Replimune Group, Inc. (REPL)

7.71 -0.19 (-2.41%) USD  |  NASDAQ  |  Jan 23, 16:00
7.715 0.00 (0.00%) After-Hours: 20:00
More

Replimune Group Research and Development Expense (TTM): 218.21M for Sept. 30, 2025

Research and Development Expense (TTM) Chart

View Research and Development Expense (TTM) for REPL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
CorMedix, Inc. 12.46M
Verastem, Inc. 103.74M
Anavex Life Sciences Corp. 37.59M
Ocugen, Inc. 35.49M
AnaptysBio, Inc. 152.43M